Mitiglinide: Difference between revisions

Jump to navigation Jump to search
m (Protected "Mitiglinide": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
No edit summary
 
(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{Editor Help}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 462252797
| IUPAC_name = (2''S'')-2-benzyl-4-[(3a''R'',7a''S'')-octahydro-2''H''-isoindol- 2-yl]-4-oxobutanoic acid
| image = Mitiglinide.svg
 
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|mitiglinide}}
| routes_of_administration = oral


{{drugbox
<!--Identifiers-->
| IUPAC_name = (-)-2(''S'')-Benzyl-4-(cis-perhydroisoindol-2-yl)butyric acid
| CAS_number_Ref = {{cascite|changed|??}}
| image = Mitiglinide.svg
| CAS_number = 145375-43-5
| CAS_number = 207844-01-7
| ATC_prefix = A10
| ATC_prefix = A10
| ATC_suffix = BX
| ATC_suffix = BX08
| ATC_supplemental =  
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 471498
| PubChem = 121891
| PubChem = 121891
| DrugBank =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| C = 19 | H = 25 | N = 1 | O = 3
| DrugBank = DB01252
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 108739
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = D86I0XLB13
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01854
 
<!--Chemical data-->
| C=19 | H=25 | N=1 | O=3  
| molecular_weight = 315.41 g/mol
| molecular_weight = 315.41 g/mol
| bioavailability =  
| smiles = O=C(O)[C@@H](Cc1ccccc1)CC(=O)N3C[C@H]2CCCC[C@H]2C3
| protein_bound =
| InChI = 1/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1
| metabolism =  
| InChIKey = WPGGHFDDFPHPOB-BBWFWOEEBF
| elimination_half-life =  
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| licence_JP = Glufast
| StdInChI = 1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1
| licence_US =  
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| pregnancy_category =
| StdInChIKey = WPGGHFDDFPHPOB-BBWFWOEESA-N
| legal_status =
| routes_of_administration = oral
}}
}}
__NOTOC__
{{SI}}
{{SI}}
'''Mitiglinide''' (trade name '''Glufast®''') is a [[drug]] for the treatment of [[type 2 diabetes]].
{{CMG}}
 
==Overview==
 
'''Mitiglinide''' ([[International Nonproprietary Name|INN]], trade name '''Glufast''') is a [[drug]] for the treatment of [[type 2 diabetes]].<ref name="pmid18803455">{{cite journal |author=Malaisse WJ |title=Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients |journal=Expert Opin Pharmacother |volume=9 |issue=15 |pages=2691–8 |date=October 2008 |pmid=18803455 |doi=10.1517/14656566.9.15.2691 |url=http://www.informapharmascience.com/doi/abs/10.1517/14656566.9.15.2691}}</ref>


Mitiglinide belongs to the [[meglitinide]] class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda.  The North America rights to mitiglinide are held by Elixir Pharmaceuticals.  Mitiglinide has not yet gained [[Food and Drug Administration|FDA]] approval.
Mitiglinide belongs to the [[meglitinide]] class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda.  The North America rights to mitiglinide are held by Elixir Pharmaceuticals.  Mitiglinide has not yet gained [[Food and Drug Administration|FDA]] approval.


==Pharmacology==
==Pharmacology==
Mitiglinide is thought to stimulate [[insulin]] secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells.  
Mitiglinide is thought to stimulate [[insulin]] secretion by closing the ATP-sensitive K(+) [[ATP-sensitive potassium channel|K(ATP) channels]] in pancreatic beta-cells.


==Dosage==
==Dosage==
Mitiglinide is delivered in tablet form.
Mitiglinide is delivered in tablet form.
==References==
{{reflist|2}}


==External links==
==External links==
*[http://www.elixirpharm.com/ Elixir Pharmaceuticals] - website of the U.S. rights holder for mitiglinide.
*[http://www.elixirpharm.com/ Elixir Pharmaceuticals] - website of the U.S. rights holder for mitiglinide.
{{SIB}}
 
{{Oral hypoglycemics}}
{{Oral hypoglycemics}}
[[Category:Endocrinology]]
 
[[Category:Meglitinides]]
[[Category:Meglitinides]]
 
[[Category:Drug]]
{{WikiDoc Help Menu}}
[[Category:Amides]]
{{WikiDoc Sources}}

Latest revision as of 18:29, 10 April 2015

Mitiglinide
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
oral
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H25NO3
Molar mass315.41 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Mitiglinide

Articles

Most recent articles on Mitiglinide

Most cited articles on Mitiglinide

Review articles on Mitiglinide

Articles on Mitiglinide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Mitiglinide

Images of Mitiglinide

Photos of Mitiglinide

Podcasts & MP3s on Mitiglinide

Videos on Mitiglinide

Evidence Based Medicine

Cochrane Collaboration on Mitiglinide

Bandolier on Mitiglinide

TRIP on Mitiglinide

Clinical Trials

Ongoing Trials on Mitiglinide at Clinical Trials.gov

Trial results on Mitiglinide

Clinical Trials on Mitiglinide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Mitiglinide

NICE Guidance on Mitiglinide

NHS PRODIGY Guidance

FDA on Mitiglinide

CDC on Mitiglinide

Books

Books on Mitiglinide

News

Mitiglinide in the news

Be alerted to news on Mitiglinide

News trends on Mitiglinide

Commentary

Blogs on Mitiglinide

Definitions

Definitions of Mitiglinide

Patient Resources / Community

Patient resources on Mitiglinide

Discussion groups on Mitiglinide

Patient Handouts on Mitiglinide

Directions to Hospitals Treating Mitiglinide

Risk calculators and risk factors for Mitiglinide

Healthcare Provider Resources

Symptoms of Mitiglinide

Causes & Risk Factors for Mitiglinide

Diagnostic studies for Mitiglinide

Treatment of Mitiglinide

Continuing Medical Education (CME)

CME Programs on Mitiglinide

International

Mitiglinide en Espanol

Mitiglinide en Francais

Business

Mitiglinide in the Marketplace

Patents on Mitiglinide

Experimental / Informatics

List of terms related to Mitiglinide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.[1]

Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells.

Dosage

Mitiglinide is delivered in tablet form.

References

  1. Malaisse WJ (October 2008). "Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients". Expert Opin Pharmacother. 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455.

External links

Template:Oral hypoglycemics